Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Phase 4

Completed

• Conditions: Influenza
• Interventions: Biological: H1N1 influenza A Vaccine (PANFLU.1); Biological: Trivalent Inactivated Influenza Vaccine (ANFLU)

• Registration Number: NCT01008137
• Lead Sponsor: Sinovac Biotech Co., Ltd

Brief Summary

A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10
• Study First Submitted: 2009-10-29
• Study First Submitted QC: 2009-11-03
• Study First Posted: 2009-11-05
• Primary Completion: 2009-12
• Study Completion: 2010-01
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-26
• Last Update Posted: 2012-11-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Healthy male or female aged between 18 and 60
2. Be able to show legal identity card for the sake of recruitment
3. Volunteers are able to understand and sign the informed consent

Exclusion Criteria

1. Cases, cured cases and close contact of influenza A (H1N1) virus

2. History of H1N1 vaccine or seasonal influenza vaccine administration

3. Women of pregnancy, lactation or about to be pregnant in 60 days

4. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc

5. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain

6. Autoimmune disease or immunodeficiency

7. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids

8. Diabetes mellitus (type I or II), with the exception of gestational diabetes

9. History of thyroidectomy or thyroid disease that required medication within the past 12 months

10. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years

11. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws

12. Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study

13. Seizure disorder other than:

    • Febrile seizures under the age of two years old
    • Seizures secondary to alcohol withdrawal more than 3 years ago, or
    • A singular seizure not requiring treatment within the last 3 years

14. Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen

15. Guillain-Barre Syndrome

16. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)

17. History of any blood products within 3 months before the dosing

18. Administration of any other investigational research agents within 30 days before the dosing

19. Administration of any live attenuated vaccine within 30 days before the dosing

20. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing

21. Be receiving anti-TB prophylaxis or therapy currently

22. Axillary temperature > 37.0 centigrade at the time of dosing

23. Psychiatric condition that precludes compliance with the protocol:

    • Past or present psychoses
    • Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
    • Disorder requiring lithium
    • Suicidal ideation occurring within five years prior to enrollment

24. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1: Day 0-PANFLU.1; Day 21-ANFLU	H1N1 influenza A Vaccine (PANFLU.1)	50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
Group 1: Day 0-PANFLU.1; Day 21-ANFLU	Trivalent Inactivated Influenza Vaccine (ANFLU)	50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
Group 2: Day 0-ANFLU; Day 21-PANFLU.1	H1N1 influenza A Vaccine (PANFLU.1)	50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
Group 2: Day 0-ANFLU; Day 21-PANFLU.1	Trivalent Inactivated Influenza Vaccine (ANFLU)	50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
Group 3: Day 0-PANFLU.1+ANFLU	H1N1 influenza A Vaccine (PANFLU.1)	50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
Group 3: Day 0-PANFLU.1+ANFLU	Trivalent Inactivated Influenza Vaccine (ANFLU)	50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.

Primary Outcome Measures

Name	Time	Method
Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine	6 months

Secondary Outcome Measures

Name	Time	Method
Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults	3 months
Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults	3 months

Trial Locations

Locations (1)

Beijing Centers for Diseases Control and Prevention; 🇨🇳 Beijing, China